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Troglitazone halts diabetic glomerulosclerosis by blockade of The progression of renal complications associated with
mesangial expansion. long-term, poorly controlled diabetes mellitus occurs in
Background. Renal complications of long-term, poorly con- humans over a time course of 10 to 25 years. The histo-trolled type 2 diabetes mellitus include glomerulosclerosis and
architectural changes associated with disease progressioninterstitial fibrosis. The onset and progression of these compli-
are well described in the literature and include glomeru-cations are influenced by underlying pathophysiologies such
as hyperglycemia, hypertriglyceridemia, and hypercholesterol- lar hypertrophy, thickening of the glomerular basement
emia. Troglitazone, a thiazolidinedione, has been shown to membrane (GBM), mesangial expansion, afferent and
ameliorate these metabolic defects. However, it was not known efferent arteriolar hyalinosis, and interstitial fibrosis [1–3].whether therapeutic intervention with troglitazone would pre-
These structural changes have been shown to correlatevent the onset and progression of glomerulosclerosis.
with alterations in synthesis and degradation of the mac-Methods. Sixty male ZDF/Gmie rats and 30 age-matched
Zucker lean rats were in the study. The ZDF/Gmie rats were romolecular constituents of the extracellular matrices
divided into two groups, one in which blood glucose levels comprising the glomerulus and associated tissues [4–20].
were uncontrolled (30 animals) and another (30) in which blood Thickening of the GBM is known to occur in individu-glucose was controlled via dietary administration of troglita-
als in the early stages of diabetes mellitus [21–23] andzone. Ten animals from each group were sacrificed at one, three,
has been thought to contribute to the proteinuria seenand six months into the study. The kidneys were harvested
and processed for immunostaining with BM-CSPG, a marker in diabetes. However, the description of a potentially
for mesangial matrix. Images of 200 glomeruli per animal were more critical lesion, that is, the progressive disruption
captured using digital imaging microscopy, and the index of
of the ordered extracellular matrix domains within themesangial expansion (total area mesangium/total area of tuft)
glomerulus known as mesangial expansion, was first pro-per glomerular section was measured.
Results. The administration of troglitazone ameliorated the vided in the elegant morphologic studies of both Osterby
metabolic defects associated with type 2 diabetes mellitus. [23, 24] and Steffes and Mauer [25–27]. Earlier immuno-
Moreover, the glomeruli from tissue sections of animals given histochemical studies from our laboratory corroborated
troglitazone showed no mesangial expansion when compared
those results in part by showing that a macromolecularwith normoglycemic control animals, whereas the uncontrolled
constituent of the normal mesangial matrix basementdiabetic animals showed significant mesangial expansion at all
time intervals. membrane-specific chondroitin sulfate proteoglycan [28]
Conclusions. Therapeutic intervention with the thiazolidine- (BM-CSPG; referred to as bamacan [29]) becomes ab-
dione troglitazone halts the early onset and progression of normally associated with the glomerular capillary wall [30]mesangial expansion in the ZDF/Gmie rat, preventing the
in an animal model of type 1 diabetes mellitus, possiblydevelopment of glomerulosclerosis in this animal model of type
as a result of uncontrolled mesangial expansion.2 diabetes mellitus.
In this study, we return to the issue of mesangial expan-
sion in the male Zucker diabetic fatty (Gmi ZDF fa/fa)
1 See Editorial by Steffes, p. 2592 rat, a model of type 2 diabetes. The male ZDF rat is an
obese, insulin-resistant, and hyperinsulinemic animal thatKey words: thiazolidindiones, proteoglycans, type 2 diabetes mellitus,
interstitial fibrosis, ZDF/Gmie rat, glomerulosclerosis. develops impaired glucose tolerance by six weeks of age.
By 12 weeks of age, b-cells fail to secrete insulin in response
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ment of hyperglycemia, normalizes glucose tolerance, were harvested at necropsy. To enhance tissue penetra-
tion of fixative, two transverse cuts made in the kidneyand corrects the dyslipidemia in this model [32].
Troglitazone has been reported to correct albuminuria flanking the pelvis, and the entire kidney was fixed by
immersion fixation in Clark’s solution (75% ethanol andin streptozotocin-treated diabetic rats [33]. We therefore
examined the long-term effects of troglitazone treatment 25% acetic acid) [35]. Postfixation, the kidneys were
removed from the fixative, blotted to remove excess liq-on the progression of renal histopathology in the sponta-
neously diabetic ZDF rat, using the pattern of immuno- uid, weighed, and subsequently processed for paraffin
embedding as previously described [28, 34]. Specimenhistochemical staining of BM-CSPG as an indicator of
mesangial area/matrix domain within a glomerulus in preparation for digital imaging microscopy studies was
as follows. In order to maximize the number of potentialorder to determine whether therapeutic intervention
with troglitazone would prevent the entry/progression targets/slide, during microtomy, each tissue section was
collected in steps of 500 mm, that is, section 2 on theof glomeruli into the sclerotic process.
slide was 500 mm deeper into the block than section 1.
Four 4 mm tissue sections were mounted per slide; there-
METHODS
fore, each microscope slide represented a 2 mm excur-
Animals and animal care sion into the tissue specimen. Single-label immunohisto-
chemistry for BM-CSPG was performed as previouslyZucker diabetic fatty rats (ZDF/Gmie fa/fa; Genetic
Models Inc., Indianapolis, IN, USA) were fed a diet of described [34, 36]. The same lot of monoclonal antibody
and secondary antibody was used for all observations dur-Purina 5008 chow with or without troglitazone (ZDF/
TRO) as an admixture: 6 mg/g chow for the first 12 weeks ing the course of the study to minimize error in staining
intensities caused by lot-to-lot variations in antibody titer.and 12 mg/g chow between weeks 13 and 25. Because
of the gain in weight of the troglitazone-treated animals
Digital image acquisitionduring the first 12 weeks, the adjustment in the amount
of troglitazone in the diet during weeks 13 through 25 Immunostained slides were observed using a Leitz Or-
tholux microscope equipped for epifluorescent illumina-was done to maintain the dose of troglitazone in the
therapeutic range of the drug. Troglitazone treatment tion. All glomeruli were imaged using a 340 objective
magnification. A total of 200 glomeruli was digitized forwas begun when the animals were six weeks of age.
Controls were lean Zucker littermates (ZL 5 ZDF/Gmi each animal. The glomeruli were targeted and acquired
in a sequential manner starting from the outer cortex,fa/1 or 1/1; Genetic Models Inc.) fed Purina 5008 with-
out troglitazone. Animals were housed in animal quar- moving in a linear path toward the corticomedullary
junction, then moving one field laterally, and then mov-ters maintained at 228C with a 12- to 12-hour fixed light-
dark cycle. Blood glucose, triglycerides, and insulin were ing back toward the outer cortex. This scanning pattern
was repeated until a total of 200 glomeruli per animal wasmonitored weekly. Blood was collected from the tail
vein, and cholesterol and glucose were measured on a acquired. Glomeruli that appeared to be cut tangentially
were excluded from the observation group. Images ofBeckman analyzer. Triglycerides were measured colori-
metrically using a Boehringer Triglycerides assay (Boeh- glomeruli were digitized using a Dage-MTI (Michigan
City, IN, USA) CCD-100 monochromatic camera, theringer Mannheim, Indianapolis, IN, USA). Insulin con-
centrations were determined on duplicate samples using signal from which was ported to a PowerPC 9600 (Apple
Computer Corp., Cupertino, CA, USA) hosting an LG-3radioimmunoassay (Linco Research, Inc., St. Charles,
MO, USA). imaging board (Scion Corp., Frederick, MD, USA). Both
image acquisition and data analysis were performed us-
Morphology ing the imaging software, IPLabSpectrum (Scanalytics
Corp., Fairfax, VA, USA).Immunological reagents. The characterization of core
protein-specific monoclonal antibodies for BM-CSPG, a Image analysis and morphometry measurement of glo-
merular area (At) were performed by manually tracingchondroitin sulfate proteoglycan present in the mesan-
gial matrix, has been previously described [28, 34]. Sec- the perimeter of the capillary tuft cut in transverse sec-
tion using a linetool subroutine resident within the im-ondary antibodies (goat anti-mouse IgG) conjugated to
fluorescein were purchased from Jackson Immunore- aging software package. The area of BM-CSPG immuno-
reactivity within the arborized region of the mesangiumsearch (Malverne, PA, USA). The discrete immunolocal-
ization of BM-CSPG to the mesangial matrix allowed us was used to delineate the extent of mesangium within
each glomerular section (Am). The measurement of theto use this tool to (1) identify those glomeruli that had
entered the sclerotic pathway, and (2) track and measure area of BM-CSPG immunostaining was performed using
a segmentation tool resident within the imaging softwarethe degree of mesangial expansion in glomeruli in kidney
sections from each animal. package. The mean glomerular volume was estimated
using this equation:Light microscopy specimen preparation. The kidneys
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Table 1. Physiological parameters
Blood glucoseBody weight Kidney weight Body wt/kidney wt Triglycerides Cholesterol
(nonfasting) Insulin
g mg/dL ng/dL mg/dL
Normal range (90–200) (0.5–4.0) (50–150) (50–120)
ZL (t 50) 14663 ND ND 13763 0.7860.13 7461 8166
Obese ZDF (t50) 15566 ND ND 14664 5.8760.62a 8062b 152612a
ZL (t 54 weeks) 28864 ND ND 13161 1.0860.17 13968 6261
Obese ZDF (t54 weeks) 34164a,c ND ND 447 625a,d 13.3261.26a 1107666a,d 9063a
Obese ZDF troglitazone-treated
(t54 weeks) 39669a ND ND 131 62 8.8660.62a 12065 8663a
ZL (t 512 weeks) 38968 1.5260.03 0.0039 14363 1.460.3 13468 5861
Obese ZDF (t512 weeks) 44467a,c 2.1960.06 0.0049a 675625a,d 3.560.4d 813685a,d 15764a,c
Obese ZDF troglitazone-treated
(t512 weeks) 657614a 1.9460.07 0.0028 16263b 20.961.6a 362616b 9064b
ZL (t 525 weeks) 45067 1.5160.03 0.0034 14363 1.560.4 22869 6061
Obese ZDF (t525 weeks) 44568d 2.8760.09 0.0064a 584618a,d 2.160.2d 17046243a,c 242625a
Obese ZDF troglitazone-treated
(t525 weeks) 810616a 2.0560.06 0.0025 14063 5.860.5a 331626 10665a
Abbreviation: ND, not done.
a P , 0.001 compared to ZL
b P , 0.05 compared to ZL
c P , 0.05 compared to troglitazone-treated obese ZDF
d P , 0.001 compared to troglitazone-treated obese ZDF
VG 5 b/K 3 [AG]3/2 Troglitazone ameliorates hyperglycemia long term
Fasting hyperglycemia was observed in all untreatedwhere b 5 1.38 (sphere constant) and K (a distribution
ZDF rats by three weeks (Table 1). Blood glucose levelscoefficient) 5 1.10 [37, 38]. Mesangial volume fraction
in these animals were significantly different from both(VvMes), an index of mesangial expansion, was automati- ZL animals (P , 0.001) and ZDF/TRO animals (P ,
cally calculated by the image analysis software as the
0.001). Blood glucose levels from ZL and ZDF/TRO
ratio Am/At [39]. animals were not significantly different. After 12 weeks
of study, the average fasting blood glucose rose to 675 6
Statistics
25 mg/dL in the untreated ZDF group. The ZL lean
Differences between treatment groups were deter- animals had glucose levels of 143 6 3 mg/dL (P , 0.001
mined using the analysis of variance (ANOVA) subrou- vs. untreated ZDF). ZDF/TRO animal blood glucose
tine in the application Statview (SAS, Cary, NC, USA), values averaged 162 6 3 mg/dL (P , 0.001 vs. untreated
and statistical significance between groups was deter- ZDF rats and P 5 NS vs. ZL). By week 25, ZDF diabetic
mined using Bonferroni/Dunn’s test within the same ap- animals remained hyperglycemic, while blood glucose
plication. from ZL and ZDF/TRO animals was virtually indistin-
guishable (Table 1).
Troglitazone ameliorates hyperinsulinemia long termRESULTS
Insulin levels in the ZDF animals were significantlyAnimal body weight
elevated relative to the ZL controls at the beginning ofAnimal weight for all groups is shown in Table 1. On
the study (Table 1). At four weeks, the insulin levels ofnormal chow, diabetic ZDF animals were significantly
the untreated ZDF animals had risen from 5.87 6 0.62
heavier than lean controls at all ages (P , 0.001). ZDF/
to 13.32 6 1.26 ng/dL. These values were significantly
TRO animals were significantly heavier than either the different from the ZL control (P , 0.001) and the ZDF/
untreated ZDF animals (P , 0.05) or ZL control animals TRO (P , 0.001). Also, insulin values from the ZL
(P , 0.001) after 4 weeks and remained so after 12 weeks animals were significantly different from the troglita-
(P , 0.05 and P , 0.001 for untreated ZDF and ZL zone-treated ZDF (P , 0.001). By week 12, insulin levels
animals, respectively) of treatment. Differences between in ZDF diabetic animals had fallen to levels that were not
ZDF/TRO animals and ZL controls or ZDF diabetic different from the control ZL animals. This is because of
animals were magnified by 25 weeks. ZDF diabetic ani- well-documented b-cell failure in this model [31]. Circu-
mals had begun to lose weight between weeks 21 and lating insulin levels in the ZDF/TRO animals continued
25, and by week 25, there was no difference between to rise until 12 weeks (they were 20.9 6 1.6 ng/dL). This
value significantly differed from the values for the ZLthe ZL and ZDF groups.
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controls and the untreated ZDF animals (P , 0.001). increased concomitantly at one, three, and six months.
In addition, none of the ZL animals examined at anyDuring the first 12 weeks of the study, a gradual weight
gain in the animals was observed, despite the fact that time interval had any significant interstitial fibrosis.
In contrast, at one month, the glomeruli from the un-the troglitazone-treated animals maintained a consistent
level of food intake. This unexpected weight gain, cou- treated ZDF animals appeared to be slightly hypertro-
phic. Morphometry studies (Table 2) showed that thepled with no apparent change in dietary intake, led to a
net reduction in the troglitazone dose per gram of body area of the glomerular tuft and mesangial area in these
animals also increased over the one- to six-month timeweight. To correct for this situation, at week 12 the dose
of troglitazone was increased to compensate for this interval. Accordingly, glomerular volume followed the
same trend. All of the former morphologic parametersweight gain, and the circulating insulin levels began to
drop within a week (data not shown). Insulin levels re- were significantly different from the ZL animals at all
time intervals examined (P , 0.001). By three monthsmained stable at the troglitazone-treated animals at 5 to
6 ng/dL for the duration of the experiment. It should be of untreated diabetes, glomeruli that were in the sclerotic
process were markedly evident, and the presence of tu-emphasized that despite this lower effective dose and
the rise in circulating insulin, these animals remained bular damage was noted, becoming progressively worse
by six months (Figs. 1B, 2, and 3). Interestingly, in thenormoglycemic (Table 1). At the 25-week time point,
circulating insulin levels in the ZDF/TRO animals were connective tissue between the affected tubules, BM-
CSPG–associated immunofluorescence was present, a5.8 6 0.5 ng/dL. This value was significantly higher than
the value for ZL and ZDF diabetic animals (P , 0.001). finding that had not been reported in the earlier studies
in the type 1 diabetic rat model (Fig. 3).ZL and ZDF diabetic animals did not differ from one
another at 25 weeks. During the same time course, morphometry of glomer-
uli from ZDF/TRO animals showed that glomerular hy-
Troglitazone ameliorates hypertriglyceridemia pertrophy and mesangial hypertrophy also occurred in
long term these animals, albeit not as great of a change as seen in
the ZDF animals (Table 2). When glomerular areas ofAt the beginning of the study, triglyceride levels from
obese animals were higher than in the ZL controls all three groups were normalized to body weight, the
glomeruli of the ZDF/TRO animals were not hypertro-(Table 1). By week 4, untreated ZDF animals had circu-
lating triglycerides almost tenfold higher than were phied (data not shown). The mesangial volume fraction
(VvMes) increased in both groups of diabetic animalsfound in either ZL or ZDF/TRO animals (P , 0.001).
Triglycerides were slightly decreased at 12 weeks in the over the duration of the study. However, the glomeruli
from the ZDF showed the greatest amount of expansionuntreated ZDF animals (because of a very low triglycer-
ide level in one animal), but increased significantly (P , over time (41.3% increase) when compared with the
ratio seen in the control animals increase for ZDF/TRO0.001) at 25 weeks. Circulating triglycerides were not
different between ZL and ZDF/TRO animals at 4 weeks, animals (3.44% increase). The glomeruli from the ZL
animals showed no change in mesangial expansion dur-but were significantly different at 12 weeks (134 6 8 vs.
362 6 16 mg/dL). This may have been due to the lower ing the same time period.
To assess the functional impact of troglitazone admin-troglitazone dose. At 25 weeks, there was no difference
between ZL ZDF/TRO animals (Table 1). istration in these animals, urinary protein levels were
measured for animals in all groups at six months. TheAlso shown in Table 1 are the results of cholesterol
determinations. Cholesterol levels in ZDF and ZDF/ ZL animals had the least amount of protein (7.8 mg
protein/mg creatinine). The urine of the ZDF/TRO ani-TRO animals were significantly higher than the ZL ani-
mals at all time points. ZDF/TRO animals had lower mals had a slight elevation in urinary protein (12.6 mg
protein/mg creatinine; Table 2), whereas the urine of thecholesterol than diabetic ZDF animals, but the differ-
ence was only significant at the 12-week time point (Ta- ZDF animals had a substantial amount of protein present
(28.6 mg protein/mg creatinine). These urinary proteinble 1).
levels, in turn, showed a high degree of correlation
Troglitazone prevents mesangial expansion in (0.986) with the observed mesangial expansion.
diabetic animals
Troglitazone normalizes pancreatic islet morphologyExamination of kidney sections from ZL animals from
all age groups showed that the majority of the glomeruli Figure 4 shows pancreatic islet morphology from lean
control animals, diabetic animals, and troglitazone-treatedpresent in these animals were normal with respect to
BM-CSPG distribution (Fig. 1A). Morphometry of glo- animals. As has been previously noted, disruption of
islet morphology can be seen in the sections taken frommeruli from the ZL animals showed a trend for increas-
ing size of the glomeruli as the animals aged (Table untreated diabetic animals (Fig. 4C, D) [31]. There is a
marked hyperplasia of the b-cell mass with a deposition2). In accord, the mesangial area in these animals also
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Fig. 1. Photomicrographs of sections of kidney from ZL (A), ZDF (B), and ZDF/TRO (C ) animals (t 5 6 months) immunostained with a
monoclonal antibody against BM-CSPG. In both (A) and (C), the distribution of BM-CSPG in the glomeruli has an arborized appearance, reflecting
the normal pattern of mesangial matrix within the glomerulus. In contrast, in a glomerulus from a ZDF animal (B), an area of focal segmental
sclerosis can be seen (arrow); BM-CSPG immunostaining occurs uniformly throughout the sclerotic region. Final magnification 3400.
Table 2. Morphologic parameters
Tuft area Mesangial area
Time from Glomerular volume Urinary protein
onset of study Animal group m2 106 m3 VvMes mg protein/mg creatinine
1 Month Lean control 209126114 63566113 3.8260.032 0.2960.0045 ND
Untreated 257346112ad 84676105ad 5.2060.034ad 0.3360.0037ad ND
Troglitazone treated 218776112a 6068695 4.0860.032a 0.2860.0039a ND
3 Months Lean control 235696217 6185689 4.6560.134 0.2660.0032 ND
Untreated 313656177ad 111956121ad 7.0260.059ad 0.3660.0037ad ND
Troglitazone treated 277356139a 7110677a 5.8460.044a 0.2660.0024 ND
6 Months Lean control 255296138 75226103 5.1460.042 0.2960.0035 8.362
Untreated 356316204ad 146206154ad 8.5260.073ad 0.4260.0038ad 28.665ac
Troglitazone treated 319886162a 96766106a 7.2360.055a 0.3060.0029 12.663
Data are 6 SEM. Abbreviations are: At, tuft area; Am, mesangial area; VvMes, mesangial volume fraction.
a P , 0.001 compared to ZL
b P , 0.05 compared to ZL
c P , 0.05 compared to troglitazone-treated obese ZDF
d P , 0.001 compared to troglitazone-treated obese ZDF
of collagen (Fig. 4C). Furthermore, the a cells and d rat for at least six months. Troglitazone treatment ame-
liorates both hypertriglyceridemia and hyperinsulinemiacells no longer form a capsule surrounding the islet (Fig.
4D). As can be seen in Figure 4E and F, troglitazone- when maintained at a 400 mg/kg dose. One possible
mechanism for these effects is that troglitazone-inducedtreated animals have islet morphology that is indistin-
improvement of peripheral insulin resistance results inguishable from control animals with a-cells and d-cells
marked improvement in islet morphology and normal-encapsulating a tight b-cell mass. Similar observations
ization of b-cell function. This may be due to alleviationhave been reported previously for regranulation and
of demands on the b cell for increased insulin productionmorphology of islets in the diabetic db/db mouse [40].
to compensate for insulin resistance.Islet architectural changes correlate with b-cell failure
Because of the significant morbidity and mortality as-in the ZDF rat [31, 41]. Preservation of normal metabolic
sociated with the onset and progression of nephropathyparameters in these animals is reflected in the preserva-
in individuals afflicted with diabetes mellitus, one aspecttion of normal islet architecture and the retention of
of our study focused on the efficacy of therapeutic inter-b-cell function.
vention with troglitazone in either slowing or preventing
this process from occurring. Although thickening of the
DISCUSSION GBM has been viewed as an indicator of structural
Our study shows that the insulin-sensitizing effect of changes in the early stages of the disease, its onset (,3
troglitazone treatment has long-term positive effects on years duration) does not always correlate with the onset
virtually every derangement accompanying diabetes in of functional changes as indicated by markers such as
the ZDF rat. Our study shows that troglitazone treat- microalbuminuria [1]. Mesangial expansion, a structural
change that has been thought to occur later in the pro-ment prevents the onset of hyperglycemia in the ZDF
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Fig. 2. A low-power micrograph showing BM-CSPG immunostaining of sections of kidney from (A ) ZL (control animals), (B) ZDF (untreated
diabetic animals), and (C ) ZDF/TRO (troglitazone-treated animals). All sections in this panel are from animals from the six-month time interval.
The section from the untreated diabetic animal (B) shows hypertrophic (open arrow) and sclerosed glomeruli (arrows), and tubules with distorted,
thickened basement membranes are prominently stained with the BM-CSPG antibodies. Such damage was not evident in any of the sections
examined from either ZL (A) or ZDF/TRO (B). Final magnification 3400.
gression of diabetic nephropathy, correlates with both In the context of the current study, the extent of glo-
merular immunostaining of BM-CSPG was used to de-microalbuminuria and macroalbuminuria [1].
Mesangial expansion, the increase in the volume of marcate the extent of mesangial matrix present within
the glomeruli of normoglycemic and diabetic animals.the mesangium relative to the volume of the glomerular
capillary tuft, can also be viewed in another light, that The rationale for using BM-CSPG as a marker was two-
fold. First, our previous immunohistochemistry studiesis, the gradual abrogation of the discrete organization
of extracellular matrix domains in the glomerulus. Early in the type 1 diabetic rat demonstrated that discrete
changes in the pattern of immunolocalization of BM-ultrastructure studies first demonstrated that the two
closely approximated extracellular matrices, that is, the CSPG occurred very early in the onset of the disease
(t 5 1 month duration of uncontrolled diabetes mellitus)mesangial matrix and GBM, were morphologically dis-
tinct in appearance [42, 43]. Subsequent immunohisto- [30]. Second, the abnormal association of BM-CSPG
with the glomerular capillary wall was, in turn, associatedchemical studies now show that these domains are unique
in their construction, in that each matrix domain is com- with focal displacement/detachment of endothelial cells
from the GBM as well as effacement of podocyte footposed in part of specific matrix molecules or their iso-
forms [34, 44–46]. processes. Thus, we believe that the marker was sensitive
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Fig. 3. A higher magnification of an area of
tubular damage from the kidney of an ZDF
animal with six month duration of uncontrolled
diabetes mellitus. Several glomeruli are pres-
ent in this field surrounding an area of dam-
aged tubules (arrow). The basement mem-
branes in this cluster of tubules are abnormally
thickened when compared with the basement
membranes of tubules directly adjacent (right)
to the damaged cluster. Interestingly, besides
staining the capillaries that lie in the intersti-
tial areas between the damaged tubules (inset,
higher magnification), BM-CSPG immuno-
stains irregular strands of material that do not
appear to associated with either the tubular
or capillary basement membranes (arrows).
Final magnification 3100; inset 3400.
enough to detect subtle alterations in glomerular infra- the true extent of mesangial matrix [23, 25–27]. Because
of this recent technology, we were able to measurestructure at a time far before any functional deficits could
be measured. readily the extent of mesangium in a significant number
of glomeruli (N 5 200 per animal). Our data show thatConsistent with the results of other studies, our mea-
surements show that the response to uncontrolled diabe- at one month, mesangial expansion in the untreated dia-
betic animals, as indicated by VvMes, was significantlytes mellitus in this animal model results in glomerular
hypertrophy and mesangial expansion. However, our different (P , 0.001) than either the normoglycemic or
troglitazone-treated diabetic animals. To our knowledge,study shows that this response may not be sequential as
previously thought: that is, that glomerular hypertrophy this is the first report of the measurement of a consistent,
significant mesangial expansion occurring in the earliestoccurs first, and is followed later by mesangial expansion.
Rather, our data indicate that glomerular hypertrophy stages of nephropathy. Our data suggest that mesangial
expansion should not be categorized as a late-stageand mesangial expansion occur in the diabetic rats almost
concurrently, as early as one month’s duration of un- change, since its genesis may actually occur in the earliest
stages of the progression of glomerulosclerosis.treated diabetes mellitus. The discordance of our data
with earlier studies can be readily explained by the fact In the case of the ZDF/TRO animals, glomerular hy-
pertrophy occurred at all time intervals when comparedthat those prior studies relied solely on morphology/
stereology to detect mesangial expansion and did not with control animals (P , 0.001); however, the degree
of glomerular hypertrophy for the ZDF/TRO animalshave mesangium-specific probes to assist in demarcating
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Fig. 4. Islet morphology of ZL rats (A and B), ZDF rats (C and D), and ZDF/TRO rats (E and F ) at 18 weeks of age. Adjacent sections of
pancreas were stained with antibodies to insulin (A, C, and E) for b cells or glucagon/somatostatin (B, D, and F) for a and d cells. The pancreata
from the ZDF animals (C and D) are hypertrophied in comparison to those from the ZL (A and B) and ZDF/TRO (E and F). Final magnification
3400.
was less that that seen in the ZDF animals (P , 0.001) sion in the ZDF/TRO animals was also reflected in the
fact that a significant difference in proteinuria was notat all time intervals. Given the fact that the thiazolidine-
diones might have a direct effect on vascular smooth seen between the ZL and ZDF/TRO animals (P 5
0.3932) at the six-month interval.muscle tone [47, 48], it may be possible that the glomeru-
lar hypertrophy seen in the ZDF/TRO animals may be One question raised by our study and that of Bucking-
ham et al is, “how do the thiazolidinediones exert theirdue to changes in vascular tone at the level of the afferent
arteriole that that may be entirely independent of the renoprotective effects?” [49]. The thiazolidinediones
have direct effects on two significant metabolic abnor-diabetic pathophysiology. However, this observation re-
mains to be investigated in future studies. Although glo- malities that occur in diabetes mellitus that, when prop-
erly controlled, are known to ameliorate diabetic compli-merular hypertrophy has been associated as a factor of
disease progression, the mesangial expansion data indi- cations. First, the thiazolidinediones are capable of
normalizing hyperglycemia in the type 2 diabetic patient.cate that progression beyond the initial hypertrophy did
not occur in the ZDF/TRO animals. The lack of progres- A substantial body of literature demonstrates that pro-
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4. Brown DM, Klein DJ, Michael AF, Oegema TR: 35S-glycosami-longed hyperglycemic conditions directly affect the bio-
noglycan and 35S-glycopeptide metabolism by diabetic glomeruli
synthesis/degradation [50, 51] and glycation status [52] and aorta. Diabetes 31:418–425, 1982
5. Kanwar YS, Rosenzweig LJ, Linker A, Jakubowski ML: De-of extracellular matrices secreted by mesangial cells. Sec-
creased de novo synthesis of glomerular proteoglycans in diabetes:ond, thiazolidinediones are capable of controlling the
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